Compare ADTN & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADTN | GHRS |
|---|---|---|
| Founded | 1985 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 947.2M |
| IPO Year | 1996 | 2021 |
| Metric | ADTN | GHRS |
|---|---|---|
| Price | $14.97 | $21.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $15.50 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 2.7M | 255.2K |
| Earning Date | 05-04-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.83 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,083,807,000.00 | N/A |
| Revenue This Year | $11.09 | N/A |
| Revenue Next Year | $8.47 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.46 | N/A |
| 52 Week Low | $7.11 | $10.67 |
| 52 Week High | $18.69 | $24.66 |
| Indicator | ADTN | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 46.87 | 60.68 |
| Support Level | $14.28 | $12.41 |
| Resistance Level | $18.34 | $22.88 |
| Average True Range (ATR) | 0.94 | 1.33 |
| MACD | -0.35 | -0.07 |
| Stochastic Oscillator | 14.73 | 67.96 |
Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions segment, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support segment, which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions. It generates the majority of its revenue from the Network Solutions segment.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.